1. Home
  2. CGEN

as of 04-06-2026 3:41pm EST

$2.20
$0.06
-2.75%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Founded: 1993 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 188.2M IPO Year: 2001
Target Price: $4.00 AVG Volume (30 days): 216.3K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.13 - $2.38 Next Earning Date: 05-18-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -72.78% Revenue Growth (next year): 112.37%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: -36.69%

AI-Powered CGEN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 72.62%
72.62%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Compugen Ltd. (CGEN)

Levine Zurit

SVP, Business Development

Sell
CGEN Mar 26, 2026

Avg Cost/Share

$2.04

Shares

11,875

Total Value

$24,187.00

Owned After

29,375

SEC Form 4

Share on Social Networks: